Clinical impact of antibody formation to botulinum toxin A in children | Zendy

Herrmann Jochen | Zendy; Geth Katrin | Zendy; Mall Volker | Zendy; Bigalke Hans | Zendy; Schulte Mönting Jürgen | Zendy; Linder Michaela | Zendy; Kirschner Jan | Zendy; Berweck Steffen | Zendy; Korinthenberg Rudolf | Zendy; Heinen Florian | Zendy; Fietzek Urban M. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Clinical impact of antibody formation to botulinum toxin A in children

Author(s) -

Herrmann Jochen,

Geth Katrin,

Mall Volker,

Bigalke Hans,

Schulte Mönting Jürgen,

Linder Michaela,

Kirschner Jan,

Berweck Steffen,

Korinthenberg Rudolf,

Heinen Florian,

Fietzek Urban M.

Publication year - 2004

Publication title -

annals of neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.764

H-Index - 296

eISSN - 1531-8249

pISSN - 0364-5134

DOI - 10.1002/ana.20098

Subject(s) - antibody , botulinum toxin , neutralizing antibody , medicine , toxin , titer , antibody titer , clostridium botulinum , immunology , gastroenterology , anesthesia , biology , microbiology and biotechnology

We studied the clinical impact of neutralizing antibodies to botulinum toxin A that occurred during long‐term treatment of children between 1993 and 2001. Antibodies were found in high titers in 35 of 110 (31.8%) samples from individual patients. Antibody formation correlated with secondary nonresponse ( p < 0.001). The most significant risk factors for antibody formation were the frequency of treatments ( p = 0.0001) and the injection of a higher weight‐adapted maximum dose per treatment ( p = 0.001).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research